LAUREN LEPCHITZ: Open Payments
NPI 1023517182 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,043 in 107 payments from 20 companies in 2025. Trend: 2023 $3,224 · 2024 $4,615 · 2025 $4,043
Food & beverage: $2,488Travel & lodging: $1,556
| Company | Payments | Amount |
|---|---|---|
| Insulet Corporation | 7 | $1,837 |
| Sequel Med Tech, LLC | 15 | $383 |
| Novo Nordisk Inc | 21 | $254 |
| Novartis Pharmaceuticals Corporation | 11 | $239 |
| Tandem Diabetes Care, Inc. | 2 | $173 |
| SANOFI-AVENTIS U.S. LLC | 6 | $159 |
| Mannkind Corporation | 7 | $150 |
| Lilly USA, LLC | 8 | $146 |
| Dexcom, Inc. | 6 | $110 |
| Abbott Laboratories | 6 | $103 |
Products named: Omnipod, TWIIST, LEQVIO, t:slim X2 Insulin Pump with Control-IQ, TZIELD, AFREZZA, Ozempic, Dexcom G6 Transmitter.
Industry payments across GA — which companies pay providers there.
